<SEC-DOCUMENT>0001213900-18-013740.txt : 20181010
<SEC-HEADER>0001213900-18-013740.hdr.sgml : 20181010
<ACCEPTANCE-DATETIME>20181010161758
ACCESSION NUMBER:		0001213900-18-013740
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20181010
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20181010
DATE AS OF CHANGE:		20181010

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OptimizeRx Corp
		CENTRAL INDEX KEY:			0001448431
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-BUSINESS SERVICES, NEC [7389]
		IRS NUMBER:				261265381
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38543
		FILM NUMBER:		181116175

	BUSINESS ADDRESS:	
		STREET 1:		400 WATER ST., STE. 200
		CITY:			ROCHESTER
		STATE:			MI
		ZIP:			48307
		BUSINESS PHONE:		248-651-6558

	MAIL ADDRESS:	
		STREET 1:		400 WATER ST., STE. 200
		CITY:			ROCHESTER
		STATE:			MI
		ZIP:			48307
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>f8k101018_optimizerxcorp.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO SECTION 13 OR 15(d) OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
October 10, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>OptimizeRx Corporation</U><BR>
(Exact name of registrant as specified in its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; text-align: center; border-bottom: Black 1.5pt solid">Nevada</TD>
    <TD STYLE="width: 2%; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 32%; text-align: center; border-bottom: Black 1.5pt solid">000-53605</TD>
    <TD STYLE="width: 2%; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 32%; text-align: center; border-bottom: Black 1.5pt solid">26-1265381</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">(State or other jurisdiction<BR>
of incorporation)</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">(Commission File Number)</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">(I.R.S. Employer<BR>
Identification No.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; text-align: center; border-bottom: Black 1.5pt solid">400 Water Street, Suite 200, Rochester, MI</TD>
    <TD STYLE="width: 2%; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 49%; text-align: center; border-bottom: Black 1.5pt solid">48307</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">(Address of principal executive offices)</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">(Zip Code)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&rsquo;s telephone number, including
area code: <U>248.651.6568</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 50%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed
since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%">&#9744;</TD>
    <TD STYLE="width: 96%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Written communications pursuant to Rule 425 under the Securities Act (17CFR 230.425)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&#9744;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&#9744;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&#9744;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company&nbsp;&nbsp;&nbsp;&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SECTION 8 &ndash; Other Events</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in"><B>Item 8.01</B></TD><TD><B>Other Events</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On October 10, 2018, we issued a press release about our invitation
to speak at the 12th Annual Digital Pharma East conference being held at the Pennsylvania Convention Center in Philadelphia on
October 16-19, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The information in Item 8.01 of this Current Report on Form
8-K (including Exhibit 99.1) shall not be deemed &ldquo;filed&rdquo; for purposes of Section 18 of the Securities Exchange Act
of 1934 (the &ldquo;Exchange Act&rdquo;) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference
in such a filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SECTION 9 &ndash; Financial Statements and Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in"><B>Item 9.01</B></TD><TD><B>Financial Statements and Exhibits</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 8%"><FONT STYLE="font-family: Times New Roman, Times, Serif">99.1</FONT></TD>
    <TD STYLE="width: 92%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="f8k101018ex99-1_optimizerx.htm">Press release, dated October 10, 2018</A></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>OptimizeRx Corporation</B></FONT></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ Douglas Baker</FONT></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Douglas Baker</TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Chief Financial Officer</TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Date October 10, 2018</FONT></TD>
    </TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>f8k101018ex99-1_optimizerx.htm
<DESCRIPTION>PRESS RELEASE, DATED OCTOBER 10, 2018
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit 99.1</B></FONT></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"><IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>OptimizeRx
Invited to Co-Host Plenary Session at Digital Pharma East on October 17, 2018</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>ROCHESTER,
Mich., </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(October 10, 2018) &mdash; </FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="background-color: white">OptimizeRx
Corp. (</FONT>NASDAQ: OPRX), a leading provider of digital health messaging for the pharmaceutical industry, has been invited
to speak at the 12<SUP>th</SUP> Annual Digital Pharma East conference being held at the Pennsylvania Convention Center in Philadelphia
on October 16-19, 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bringing
together more than 1,000 participants, this conference will feature latest case studies and senior-level discussions with pharma
companies, health systems, physicians, health-tech companies, startups and non-traditional healthcare companies involved in digital
health.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
plenary session, &ldquo;Addressing Medication Adherence to Improve Quality of Care,&rdquo; will be co-hosted by Miriam Paramore,
president of OptimizeRx, at 5:00 p.m. Eastern time on October 17.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Today,
healthcare providers are increasingly measured by the outcomes their care provides, not just the number of patient visits or procedures
ordered. This requires the pharma industry to work more closely with providers to ensure successful outcomes, with the value placed
not only on the moment of care but also on the broader, longer term ability to produce positive health outcomes for patients.
This means the challenge now shifts to pharma being able to successfully and cost-effectively assist providers in delivering better
care.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
this session, Paramore and Dr. Jack Pinney of MidMichigan Health will discuss:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">How
                                         real-time patient savings, education and adherence strategies are integral parts of a
                                         value-based care strategy.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Need
                                         for pharma marketers to execute a multi-channel strategy across financial, clinical and
                                         brand support at the point-of-care.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">How
                                         digital heath has impacted Dr. Pinney&rsquo;s efforts in providing quality patient care.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Rising
drug costs are a major industry challenge,&rdquo; noted Paramore. &ldquo;However, the increase in digitally-delivered copay coupons
and savings vouchers have provided needed relief to the affordability issue.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;The
latest industry research also reveals that medication adherence improves when patients can lower their co-payments,&rdquo; continued
Paramore. &ldquo;OptimizeRx delivers patient savings opportunities directly into the physician EHR workflow at the point of prescribe,
with this improving medication adherence and patient outcomes. For this conference session, I look forward to discussing how our
technology is positively impacting the intersection of pharma, physicians and patient outcomes.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Digital Pharma East</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Digital
Pharma East is the leading marketing conference globally for life science professionals looking to learn, network and be inspired.
For more information, visit www.digitalpharmaseries.com/east.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
OptimizeRx</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B>OptimizeRx&reg; (NASDAQ: OPRX) is one of the nation&rsquo;s leading providers of digital health messaging via electronic
health records (EHRs), providing a direct channel for pharma companies to communicate with healthcare providers. The company&rsquo;s
cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization,
education, and critical clinical information. The company&rsquo;s network is comprised of leading EHR platforms like Allscripts,
Amazing Charts and Quest, and provides more than half of the ambulatory patient market with access to these benefits within their
workflow at the point-of-care. For more information, follow the company on&nbsp;Twitter,&nbsp;LinkedIn&nbsp;or visit&nbsp;www.optimizerx.com.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Important
Cautions Regarding Forward Looking Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended,
and such as in section 21E of the Securities Act of 1934, as amended. These forward-looking statements should not be used to make
an investment decision. The words 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking statements,
which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any
forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently
subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ
materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties
to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition
and other material risks.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OptimizeRx
Contact</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Doug
Baker, CFO</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel
(248) 651-6568 x807</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">dbaker@optimizerx.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Media
Relations Contact</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nicole
Brooks, Innsena Communications</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Tel)
860-800-2344</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">nicolebrooks@innsena.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investor
Relations Contact</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ron
Both, CMA</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel
(949) 432-7557</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">oprx@cma.team</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>&nbsp;</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  ^ 3H# 2(  A$! Q$!_\0
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M,;.[!$4%F9C@ #J: ."^-7QP\+? ;PA)K_BB\\F-B4M;.+#3W<F,[(U[^Y/
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M;+HVGS1E)+&W=&X*M$I'\JW_ -2\7TQC^Y__ "0>R?<^>O#WQDU_1YD%Q/\
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MD:A+XE22?P[H<"7$]HC%/M,C-B.-F'(7AB<<G;CO7U?_ ,%/C+_PS_I&0?\
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MA9@A_P!D YSBO FTM--^$^E>.;*V-Q&OBA-8DM=2NA,\R8*<LL2A68XR ".
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MP8X7T]*U/AQXPU>^UJY\,ZO!9M<Z7IEE-+>6A*K-))'EL)M 501QC\A7S?\
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&HHJ@/__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
